EUVIMEDEUVIMED entdecken
Crossref

Association of concomitant proton pump inhibitor use with worse survival outcomes in patients with advanced gastric cancer receiving ramucirumab

Takuya Kaneko, Kosuke Doki iD, Takeshi Yamada, Masato Uda, Yoshiyuki Yamamoto, Mariko Kobayashi, Kiichiro Tsuchiya, Masato Homma

British Journal of Clinical Pharmacology · 2025

DOI: 10.1002/bcp.70202 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Takuya Kaneko und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, University of Tsukuba Hospital, Ibaraki, Japan. Hauptthemen laut MEDLINE: Stomach Neoplasms, Proton Pump Inhibitors, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Vascular endothelial growth factor (VEGF)‐A binding to VEGF receptor (VEGFR)2 promotes tumour angiogenesis and progression. Proton pump inhibitors (PPIs) upregulate VEGF‐A expression in various cancers. This study examined the association between concomitant PPI use and survival outcomes in patients with advanced gastric cancer (AGC) receiving ramucirumab, a VEGFR2‐targeting monoclonal antibody, plus paclitaxel (PTX) or nab‐paclitaxel (nab‐PTX). The impact of PPI use on serum VEGF‐A concentrations was also evaluated.

Methods

This retrospective study included 152 patients with AGC receiving ramucirumab plus PTX/nab‐PTX as a second‐line therapy. Progression‐free survival (PFS) was compared between PPI and non‐PPI users. Multivariate Cox proportional hazards analysis was used to assess the prognostic factors for PFS. Serum VEGF‐A concentrations were measured in blood samples from 25 patients at baseline and on Day 14 following the first ramucirumab infusion.

Results

Median PFS was 3.7 months (95% confidence interval [CI]: 2.8–4.7) for PPI users and 4.7 months (95% CI: 4.0–5.3) for non‐PPI users (hazard ratio [HR]: 1.44; 95% CI: 1.01–2.06; P = 0.040). Multivariate analysis, adjusted for age, the Glasgow prognostic score, total gastrectomy and massive ascites, identified PPI use as a prognostic factor for PFS (HR: 1.48; 95% CI: 1.02–2.14; P = 0.038). Serum VEGF‐A concentrations were higher in PPI users than in non‐PPI users at baseline and during ramucirumab therapy.

Conclusions

Concomitant PPI use was associated with shorter PFS in patients with AGC receiving ramucirumab plus PTX/nab‐PTX, likely due to elevated serum VEGF‐A concentrations during treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsProton Pump InhibitorsAntineoplastic Combined Chemotherapy ProtocolsHumansRamucirumabMaleFemaleAntibodies, Monoclonal, HumanizedMiddle AgedRetrospective StudiesAgedPaclitaxelVascular Endothelial Growth Factor AProgression-Free SurvivalVascular Endothelial Growth Factor Receptor-2AlbuminsAdultAged, 80 and overPrognosis

Stichwörter der Autor:innen

VEGFnab‐paclitaxelpaclitaxelproton pump inhibitorramucirumab

Substanzen

RamucirumabAntibodies, Monoclonal, HumanizedPaclitaxelProton Pump InhibitorsVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-2AlbuminsVEGFA protein, human130-nm albumin-bound paclitaxelKDR protein, human

Autor:innen und Institutionen

  • Department of Pharmacy, University of Tsukuba Hospital, Ibaraki, Japan.
  • Department of Pharmaceutical Sciences, Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan.
  • Division of Gastroenterology, University of Tsukuba Hospital, Ibaraki, Japan.

ORCID-Profile: Kosuke Doki

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Kaneko, T., Doki, K., Yamada, T., Uda, M., Yamamoto, Y., Kobayashi, M., Tsuchiya, K., & Homma, M. (2025). Association of concomitant proton pump inhibitor use with worse survival outcomes in patients with advanced gastric cancer receiving ramucirumab. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70202

Vancouver

Kaneko T, Doki K, Yamada T, Uda M, Yamamoto Y, Kobayashi M, et al. Association of concomitant proton pump inhibitor use with worse survival outcomes in patients with advanced gastric cancer receiving ramucirumab. British Journal of Clinical Pharmacology. 2025. doi:10.1002/bcp.70202

BibTeX
@article{Kaneko2025,
  author = {Kaneko, Takuya and Doki, Kosuke and Yamada, Takeshi and Uda, Masato and Yamamoto, Yoshiyuki and Kobayashi, Mariko and Tsuchiya, Kiichiro and Homma, Masato},
  title = {Association of concomitant proton pump inhibitor use with worse survival outcomes in patients with advanced gastric cancer receiving ramucirumab},
  journal = {British Journal of Clinical Pharmacology},
  year = {2025},
  doi = {10.1002/bcp.70202}
}
Kostenlos starten →